International Clinical Trial: ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA(R)): A U.S. Pragmatic Multicenter Study (STREAM)

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07448610) titled 'ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA(R)): A U.S. Pragmatic Multicenter Study (STREAM)' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Novartis Pharmaceuticals

Condition: Spinal Muscular Atrophy

Intervention: Drug: Onasemnogene Abeparvovec-brve

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: July 1, 2026

Target Samp...